Abstract
Translationally controlled tumor protein (TCTP), also known as histamine-releasing factor (HRF) or fortilin, is a highly conserved protein found in various species. To date, multiple studies have demonstrated the crucial role of TCTP in a wide range of cellular pathophysiological processes, including cell proliferation and survival, cell cycle regulation, cell death, as well as cell migration and movement, all of which are major pathogenic mechanisms of tumorigenesis and development. This review aims to provide an in-depth analysis of the functional role of TCTP in tumor initiation and progression, with a particular focus on cell proliferation, cell death, and cell migration. It will highlight the expression and pathological implications of TCTP in various tumor types, summarizing the current prevailing therapeutic strategies that target TCTP.
Introduction: The Challenge of Drug Resistance and the Role of TCTP
While targeted therapies against specific drivers like HER2 or EGFR have significantly improved cancer outcomes, the emergence of drug resistance remains a critical barrier to long-term survival. There is an urgent clinical need to identify novel molecular targets that govern multiple hallmarks of cancer simultaneously. TCTP has emerged as a "master regulator" in this context. Overexpressed in numerous aggressive malignancies, TCTP acts as a biochemical "Swiss Army knife," manipulating core signaling pathways to drive proliferation, evade apoptosis, and facilitate metastasis.
Methodology: Mapping the TCTP Interactome
This review synthesizes evidence from 159 peer-reviewed studies to map the complex interactome of TCTP. The analysis focuses on its structural biology and regulatory influence across three primary domains: cell proliferation (mTORC1 and PLK1 pathways), cell death (apoptosis and autophagy), and cell migration (EMT and cytoskeletal remodeling).
Mechanisms of Action: How TCTP Drives Tumorigenesis
Activating the mTOR Growth Engine
One of TCTP's most critical roles is its function as a Guanine Nucleotide Exchange Factor (GEF) for Rheb. By facilitating the loading of GTP onto Rheb, TCTP activates the mTORC1 complex, the central engine for cellular growth and protein synthesis.
Evading the "Guardian of the Genome" and Programmed Cell Death
Beyond growth signaling, TCTP creates a potent anti-apoptotic shield. It establishes a negative feedback loop with p53, the "guardian of the genome," by promoting its degradation. Furthermore, TCTP physically blocks pro-apoptotic proteins like Bax from forming pores in the mitochondrial membrane while stabilizing pro-survival factors such as Mcl-1 and Bcl-xL.
Promoting Metastasis through Cytoskeletal Remodeling
TCTP also facilitates cancer cell mobility. It possesses a higher affinity for G-actin than the protein cofilin. By sequestering G-actin, TCTP releases active cofilin to remodel the actin cytoskeleton, a necessary step for epithelial-mesenchymal transition (EMT) and subsequent metastasis.
Clinical Implications and Therapeutic Potential
High TCTP expression is a consistent biomarker for poor clinical outcomes in breast, lung, gastric, and colorectal cancers. Interestingly, several non-oncology drugs show promise in targeting TCTP. The antidepressant Sertraline can disrupt the TCTP-p53 loop, while the antimalarial derivative Dihydroartemisinin (DHA) triggers TCTP degradation. In HER2-positive breast cancer models, DHA has been shown to restore sensitivity to standard treatments like T-DM1, suggesting a path forward for overcoming drug resistance.
Future Directions and Current Limitations
Despite its potential, several gaps remain. The specific GEF activity of TCTP toward Rheb is still under debate in some biochemical circles, and its relationship with the mTORC2 complex remains poorly understood. Most current therapeutic evidence is limited to preclinical models; transitioning these findings into human clinical trials is the essential next step for validating TCTP as a viable therapeutic target.
Summary updated